Public Release: 23-Jun-2015
“ Laboratory testing showed 44 products (59 percent) had detectible levels of CBD, but the average ratio of THC to CBD was 36-to-1”
Review of small sample of dispensary products suggests buyers at risk of overdosing or being cheated
Johns Hopkins Medicine
In a proof-of-concept study, a team led by a Johns Hopkins researcher reports that the vast majority of edible cannabis products sold in a small sample of medical marijuana dispensaries carried labels that overstated or understated the amount of delta-9-tetrahydrocannabinol (THC).
Though the scope of the study was small, the researchers say, the results of the study suggest some medical cannabis patients could be unintentionally overdosing or are being cheated by mislabeled products.
“If this study is representative of the medical cannabis market, we may have hundreds of thousands of patients buying cannabis products that are mislabeled,” says experimental psychologist Ryan Vandrey, Ph.D., an associate professor of psychiatry and behavioral sciences at the Johns Hopkins University School of Medicine and lead author of a report on the study published June 23 in the Journal of the American Medical Association.
Calling for better regulation and oversight of marijuana edibles, Vandrey and his team say patients who consume underlabeled products — meaning more THC is in the product than is stated on the label — could suffer from overdosing side effects, including extreme anxiety and psychotic reactions. Patients purchasing products that are overlabeled are not getting what they paid for, he adds.
“Caveat emptor,” or “let the buyer beware,” is “just not right” for the sale of medical marijuana, he says.
For the study, Vandrey teamed with an independent laboratory and collected 75 different edible cannabis products — baked goods, beverages and candy/chocolates — representing 47 different brands. The products were legally purchased from a sample of three medical dispensaries in each of three cities: Seattle, San Francisco and Los Angeles. “Those cities were chosen based on the location of the labs” in California and Washington, says Vandrey, “because you can’t transport these products across state lines legally.”
Comparing the THC content listed on product labels with the laboratory measures revealed only 13 products (17 percent) that were accurately labeled. When lab results differed from the product label by more than 10 percent, the team categorized those products as either under- or overlabeled. Some 17 products (23 percent) had more THC than advertised, which could lead to overdosing. The majority of products — 45 products (60 percent) — were overlabeled, meaning patients purchasing those products for their THC content are not getting the dose of medicine they believed they purchased.
“We didn’t have a guess as to how many products would have inaccurate labels,” says Vandrey, “but I was surprised it was so many.”
The team also tested the products for cannabidiol, or CBD, another of the active ingredients in cannabis believed to have medical benefit, which may also help reduce the side effects of THC.
Laboratory testing showed 44 products (59 percent) had detectible levels of CBD, but the average ratio of THC to CBD was 36-to-1. Only one product had a 1-to-1 ratio, which some research suggests is associated with fewer side effects and improved clinical benefit compared with higher ratios of THC to CBD.
“A lot of dispensary owners and medical cannabis proponents make a big case about how therapeutically beneficial CBD is,” says Vandrey, “but our testing indicates that a lot of what’s available in the edible cannabis market may have very little CBD.”
Currently, marijuana remains classified as a Schedule I substance under the U.S. Controlled Substances Act, meaning it is considered to have a high potential for abuse, no accepted medical value and lack of accepted safety for use under medical supervision. Yet 23 states and the District of Columbia permit the sale and/or use of medical marijuana, and four states and D.C. permit its sale and use for recreational purposes.
In the absence of federal regulation, says Vandrey, “the states that have medical marijuana laws need to account for the quality and testing of medical marijuana products sold to their residents.”
Other authors on the paper are Jeffrey C. Raber, Mark E. Raber, Brad Douglass and Cameron Miller of The Werc Shop laboratory and Marcel O. Bonn-Miller of the University of Pennsylvania Perelman School of Medicine.
The study was supported by the Johns Hopkins University School of Medicine and The Werc Shop laboratory, which provided testing and associated costs. Bonn-Miller reports fees and nonfinancial support from Tilray (Division of Privateer Holdings) and nonfinancial support from Americans for Safe Access.
Categories: Pharmaceutical - Medical Devices